STOCK TITAN

Collplant Biotechnologies Ltd - CLGN STOCK NEWS

Welcome to our dedicated page for Collplant Biotechnologies news (Ticker: CLGN), a resource for investors and traders seeking the latest updates and insights on Collplant Biotechnologies stock.

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) pioneers regenerative medicine solutions through its plant-based recombinant human collagen (rhCollagen) technology. This dedicated news hub provides investors and stakeholders with timely updates on clinical advancements, strategic partnerships, and product developments in 3D bioprinting, medical aesthetics, and tissue repair.

Access official press releases covering regulatory milestones, research breakthroughs, and commercial collaborations with industry leaders like AbbVie and Stratasys. Our curated collection includes updates on Vergenix™ wound care products, rhCollagen BioInk applications, and progress in regenerative breast implant development.

Discover comprehensive coverage of financial results, intellectual property expansions, and manufacturing scale-up initiatives. This resource serves as your primary source for tracking CollPlant's progress in addressing unmet needs across orthobiologics, advanced wound care, and organ manufacturing markets.

Bookmark this page for streamlined access to CLGN's latest developments in biocompatible medical solutions. Check regularly for updates on ESG initiatives, patent filings, and clinical trial outcomes that shape the company's position in the $3B+ regenerative medicine sector.

Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ: CLGN), a leader in regenerative medicine, announced a presentation by Deputy CEO Eran Rotem at the Canaccord Genuity MedTech Forum on November 17, 2022, at 2:00 p.m. ET. The presentation will overview the company's innovative human-collagen based technologies aimed at tissue regeneration and organ manufacturing. CollPlant has established agreements with Allergan and 3D Systems for product development in dermal fillers and regenerative matrices. Attendees can request one-on-one meetings with the company during the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.64%
Tags
conferences
-
Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) will be presenting an overview at the Dawson James 7th Annual Small Cap Growth Conference in Jupiter, Florida. The presentation will be led by Deputy CEO & CFO Eran Rotem on October 12 from 14:00-14:25 PM ET. Investors attending can request one-on-one meetings through conference coordinators. CollPlant specializes in regenerative and aesthetic medicine, focusing on 3D bioprinting technologies using proprietary recombinant human collagen to address tissue repair and organ manufacturing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
conferences
-
Rhea-AI Summary

CollPlant (NASDAQ: CLGN) announced its participation at the International Conference on Biofabrication in Tuscany, Italy, from September 25 to 28, 2022. The company will present on "Recombinant Human Collagen-based Bioinks for Biofabrication and Modeling Applications" on September 28 during the symposium from 9:00 AM to 10:30 AM CET. CollPlant focuses on innovative solutions in tissue regeneration and organ manufacturing using its proprietary rhCollagen technology, and will feature an exhibition booth at the conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.26%
Tags
conferences
Rhea-AI Summary

CollPlant Biotechnologies (Nasdaq: CLGN) announced participation in upcoming investor conferences. Deputy CEO and CFO Eran Rotem will engage with investors at the HC Wainwright 24th Annual Global Investment Conference on September 12-13 and the Alliance Global Partners MedTech Conference on September 21. CollPlant focuses on innovative collagen-based technologies for tissue regeneration and organ manufacturing. The company has also partnered with Allergan and 3D Systems to advance its product offerings in aesthetic and regenerative medicine.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
conferences
-
Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ: CLGN) reported its Q2 2022 financial results, revealing a GAAP revenue of $66,000, down from $691,000 the previous year, primarily due to decreased BioInk and Vergenix product sales. The company reported a net loss of $4.3 million, or $0.39 per share. Notably, CollPlant is advancing its co-development agreement with AbbVie for dermal fillers and is on track for large animal studies of its 3D bioprinted regenerative breast implant. Cash and equivalents stood at $36 million as of June 30, 2022, reflecting a strong balance sheet.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.25%
Tags
-
Rhea-AI Summary

CollPlant (NASDAQ: CLGN) is set to present at the TERMIS conference in Toronto, Canada from July 10-13, 2022. The company will showcase its revolutionary rhCollagen technology through two presentations: "RhCollagen - The Ideal Building Block For 3D Printed and Injectable Scaffolds for Regenerative Medicine" on July 13, and a poster on "Recombinant Human Collagen-Based Bioinks for Biofabrication Applications" on July 11. CollPlant focuses on advanced regenerative medicine, highlighting its innovative biomaterials aimed at tissue repair, bioprinting, and skin rejuvenation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
conferences
Rhea-AI Summary

CollPlant (Nasdaq: CLGN) announced the initiation of a large animal study for its 3D bioprinted regenerative breast implants, targeting the $2.8 billion global breast implant market. This study aims to evaluate the implants' performance, including tissue regeneration and integration and is expected to conclude within six months. CollPlant's technology utilizes plant-derived rhCollagen, which aims to reduce safety issues linked to silicone implants. The company plans to follow this study with human trials, marking significant progress in their product development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.54%
Tags
none
-
Rhea-AI Summary

CollPlant Biotechnologies (NASDAQ: CLGN) reported updates on its strategic initiatives and Q1 2022 financial results. The company is advancing its collaboration with AbbVie to develop rhCollagen-based dermal fillers and is on track to initiate a large animal study for its 3D bioprinted breast implant program in Q2 2022. As of March 31, 2022, CollPlant had cash and equivalents of $41M. Q1 revenues declined to $66,000, down from $14.5M year-over-year, largely due to a $14M upfront payment from AbbVie in 2021. The GAAP net loss was $3.9M, or $0.36 per share.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
-
Rhea-AI Summary

CollPlant (Nasdaq: CLGN) announced that CEO Yehiel Tal will moderate a virtual event hosted by the International Society for Biofabrication (ISBF) on May 2, 2022. The event, titled Biofabrication of Microphysiological Systems for Drug Discovery and Screening, aims to enhance collaboration across academia and industry, featuring experts from notable institutions. This engagement reflects CollPlant's commitment to advancing regenerative medicine through innovative technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.14%
Tags
none
Rhea-AI Summary

CollPlant (NASDAQ: CLGN), a leader in regenerative medicine, announced that Dr. Jasmine Seror will present at the Aesthetics Innovation Summit 2022 on April 20, 2022. Her presentation, titled "Novel photocurable rhCollagen implants for regenerative aesthetics applications," will be featured during the spotlight session at 11:20 AM EST. CollPlant focuses on innovative technologies utilizing rhCollagen, aimed at enhancing tissue regeneration and organ manufacturing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.46%
Tags
conferences
Collplant Biotechnologies Ltd

Nasdaq:CLGN

CLGN Rankings

CLGN Stock Data

27.72M
7.65M
10.16%
12.23%
0.04%
Biotechnology
Healthcare
Link
Israel
Rehovot